Journal of American Pharmacists Association

September-October 2009, Vol. 49, No. 5 >

Research

Patient-reported communications with pharmacy staff at community pharmacies: The Alabama NSAID Patient Safety Study, 2005–2007

Cynthia LaCivita, PharmD; Ellen Funkhouser, DrPH; Michael J. Miller, BPharm, DrPH; Midge N. Ray, RN, MSN; Kenneth G. Saag, MD, MSc; Catarina I. Kiefe, PhD, MD; Daniel J. Cobaugh, PharmD; Jeroan J. Allison, MD, MS

J Am Pharm Assoc. 2009;49:e110-e117. doi:10.1331/JAPhA.2009.09005

Article

References

text A A A

Abstract

Objectives To examine the prevalence of patient–pharmacy staff communication about medications for pain and arthritis and to assess disparities in communication by demographic, socioeconomic, and health indicators.

Design Descriptive, nonexperimental, cross-sectional study.

Setting Alabama between 2005 and 2007.

Patients 687 patients participating in the Alabama NSAID Patient Safety Study (age ≥50 years and currently taking a prescription nonsteroidal anti-inflammatory drug [NSAID]).

Intervention Not applicable.

Main outcome measures Communication with pharmacy staff about prescription and over-the-counter (OTC) NSAIDs was examined before and after adjustment for demographic, socioeconomic, and health indicators.

Results For the entire cohort (n = 687), mean (±SD) age was 68.3 ± 10.0 years, 72.8% were women, 36.4% were black, and 31.2% discussed use of prescription pain/arthritis medications with pharmacy staff. Discussing use of prescription pain/arthritis medications with pharmacy staff differed by race/gender (P < 0.001): white men (40.3%), white women (34.6%), black men (30.2%), and black women (19.8%). Even after multivariable adjustment, black women had the lowest odds of discussing their medications with pharmacy staff (odds ratio 0.40 [95% CI 0.24–0.56]) compared with white men. For the 63.0% of participants with recently overlapping prescription and OTC NSAID use, communication with pharmacy staff about OTC NSAIDs use was only 13.7% and did not vary significantly by race/gender group.

Conclusion Given the complex risks and benefits of chronic NSAID use, pharmacists, pharmacy staff, and patients all are missing an important opportunity to avoid unsafe prescribing and decrease medication adverse events.

APhA Members
Welcome to JAPha.org! Please log in below using your APhA username and password. If you need to update your account information, please go to Pharmacists.org and login using your current credentials.

Username

Password

Forgot your password?

New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

Buy 7-day-access to this article for $30
Buy 7-day-access to this issue for $75
Buy 7-day-access to JAPhA Online for $150

Register for a FREE limited account to benefit from personalization features such as alerts.

References

Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18–24.[PubMed]

American Society of Health-System Pharmacists. Nonsteroidal antiinflammatory agents. In: McEvoy GK, Ed. AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2008:2051–172.

Thomas J, Straus WL, Bloom BS. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am J Gastroenterol. 2002;97:2215–9.[PubMed][CrossRef]

Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug-drug interactions between antithrombotic medications and risk of gastrointestinal bleeding. CMAJ. 2007;117:347–51.

Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complication related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 1991;115:787–96.[PubMed]

Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in 1990s. Arch Intern Med. 2000;14:2093–9.

Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731–8.[PubMed]

Wolf MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. New Eng J Med. 1999;340:1888–99.

Chan AT, Manson Je, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006:113:1578–87.[PubMed]

Institute of Medicine. To err is human: building a safer health system.Kohn LT, Corrigan JM, Donaldson MS, Eds. Washington, DC: National Academy Press; 2000.

Institute of Medicine. Preventing medication errors: quality chasm series.Aspden P, Wolcott J, Bootman JL, Cronenwett LR, Eds. Washington, DC: National Academy Press; 2006.

Indermitte J, Reber D, Beutler M, et al. Prevalence and patient awareness of selected potential drug interactions with self-medications. J Clin Pharm Ther. 2007;32:149–59.[PubMed]

Guignard AP, Couray-Targe S, Colin C, Chamba G. Economic impact of pharmacists’ interventions with nonsteroidal anti-inflammatory drugs. Pharmacoeconomics. 2003;37:332–8.

Ibanez-Cuevas V, Lopez-Briz E, Guardiola-Chorro MT. Pharmacist intervention reduce gastropathy risk in patients using NSAIDs. Pharm World Sci. 2008;30:947–54.[PubMed]

Institute of Medicine. Unequal treatment: what healthcare providers need to know about racial and ethnic disparities in healthcare.Smedley BD, Stith AY, Nelson AR, Eds. Washington, DC: National Academy Press; 2002.

Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians‘ recommendations for cardiac catheterization. N Engl J Med. 1999;340:618–26.[PubMed]

Cobaugh DJ, Anger E, Kiefe CI, et al. Effect of racial difference on ability to afford prescription medications. Am J Health Syst Pharm. 2008;65:2137–43.[PubMed]

Fry RB, Ray MN, Cobaugh DJ, et al. Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behavior. Arthritis Rheum. 2007;57:1539–45.[PubMed]

Szeinbach SL, Fink JL. Identifying the pharmacist‘s professional status. Am Pharm. 1984;NS24(9):60–3.

Youmans SL, Schillinger D, Mamary E, Stewart A. Talk with your pharmacists: they are there to help. Ethn Dis. 2007;17(2):420.[PubMed]

U.S. Food and Drug Administration Center for Drug Evaluation and Research. Medication guide for non-steroidal anti-inflammatory drugs (NSAIDs). Accessed at www.fda.gov/medwatch/SAFETY/2008/Jan_PI/Tolectin_MG.pdf, May 30, 2008.

Morris LA, Tabak ER, Gondek K. Counseling patients about prescribed medication: 12-year trends. Med Care. 1997;35:996–1007.[PubMed]

Erickson SR, Kirking DM, Sandusky M. Michigan Medicaid recipients‘ perceptions of medication counseling as required by OBRA ‘90. J Am Pharm Assoc. 1998;38:333–8.

Svarstad BL, Bultman DC, Mount JK. Patient counseling provided in community pharmacies: effects of state regulation, pharmacists age and busyness. J Am Pharm Assoc. 2004;44:22–9.

Johnson RL, Roter D, Powe NR, Copper LA. Patient race/ethnicity and quality of patient-physician communication during medical visits. Am J Public Health. 2004;94:2084–90.[PubMed]

Schommer JC, Wiederholt JB. The association of prescription status, patient age, patient gender and patient question asking behavior with the content of pharmacist-patient communication. Pharm Res. 1997;14:145–51.[PubMed]

Hall JA, Roter DL, Katz NR. Meta-analysis of correlates of provider behavior in medical encounters. Med Care. 1988;26:657–75.[PubMed]

Youmans SL, Schillinger D, Mamary E, Stewart A. Older African American's perceptions of pharmacists. Ethn Dis. 2007;17:284–90.[PubMed]

Schommer JC, Pedersen CA, Gaither CA, et al. Pharmacists’ desired and actual times in work activities: evidence of gaps from the 2004 National Pharmacist Workforce Study. J Am Pharm Assoc. 2006;46:340–7.

Schommer JC, Wiederholt JB. A field investigation of participant and environment effects on pharmacists-patient communication in community pharmacies. Med Care. 1995;33:567–84.[PubMed]

Kirking DM. Evaluation of an explanatory model of pharmacists’ patient counseling activities. J Soc Admin Pharm. 1984;2:50–6.

Holland RW, Nimmo CM. Transitions in pharmacy practice. Part 3: effecting change: the three ring circus. Am J Health Syst Pharm. 1999;56:1758–64.[PubMed]

Bultman DC, Svarstad BL. Effects of pharmacist monitoring on patient satisfaction with antidepressant therapy. J Am Pharm Assoc. 2002;42:36–43.

Alabama Board of Pharmacy. Code of Alabama 1975 Cumulative Supplement: including act of 2009 legislature: title 34, chapter 23, practice of pharmacy act 205 legislature 1966. Accessed at www.albop.com/act205%20052709.pdf, July 17, 2009.

Shrank WH, Avorn J. Educating patients about their medications: the potential and limitations of written drug information. Health Aff (Millwood). 2007;26:731–40.[PubMed]

Miller MJ, Allison JJ, Schmitt MR, et al. Using single-item health literacy screening questions to identify patients who read written non-steroidal anti-inflammatory medicine information provided at pharmacies. J Health Commun.In press.

Raynor DK, Blenkinsopp A, Knapp P, et al. A systematic review of quantitative and qualitative research on the role of effectiveness of written information available to patients about individual medicines. Health Technol Assess. 2007;11:1–160.

Roter DL, Hall JA, Merisca R, et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998;36:1138–61.[PubMed]

Fernandez A, Viloria J, Wu E, et al. The impact of race/ethnicity and language on access on experience of care among California's commercially insured adults. Accessed at http://cpac.berkeley.edu/documents/fernandez_impact_race_eth.pdf, September 5, 2008.

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).

Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.

All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field

Comment Author(s)*(if multiple authors, separate names by comma)

Example: John Doe

Affiliation & Institution*

Comment Title*

Comment*